Can a checkpoint inhibitor deepen remission in myeloma after CAR-T?
NCT ID NCT06523621
First seen Jan 22, 2026 · Last updated May 23, 2026 · Updated 14 times
Summary
This study tests whether adding nivolumab (an immunotherapy drug) can improve the response in people with relapsed/refractory multiple myeloma who did not get a complete response from ide-cel CAR-T therapy. The trial enrolled 1 adult participant with measurable disease and good performance status. The goal is to see if nivolumab can help achieve a complete or stringent complete response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
Conditions
Explore the condition pages connected to this study.